Latest Insights - page 29 | BiopharmaTrend

AI-Designed Drug Reaches Clinical Validation: Insilico’s Rentosertib in Nature Medicine

Today, Nature Medicine published peer-reviewed Phase IIa clinical results for Rentosertib (ISM001-055), a TNIK inhibitor developed by Insilico Medicine using a generative-AI workflow. The paper details the GENESIS-IPF trial—a randomized, double-blind, …

Continue ›››

French Startup Using AI and Click Chemistry to Speed Up Microbial Detection Raises €5M

Diamidex, a Marseille-based company developing microbiological testing tools for industrial and environmental labs, has expanded the international reach of its MICA platform. The system integrates solid-phase cytometry, AI-assisted image analysis, …

Continue ›››

AI-Based Next-Generation-Phenotyping for Rare Disease Diagnosis

Rare diseases, which affect more than 300 million people worldwide, are often difficult to diagnose. Many patients wait five years or more for a correct diagnosis and are misdiagnosed at …

Continue ›››

14 Startups in AI Protein Design: Platforms, Specialists, Modular Tools

A Nobel, a venom cure, and a 200-million-protein database—by late 2024, AI design has earned recognition. David Baker from University of Washington collected the Nobel Prize in Chemistry for structure-guided engineering, sharing the honor …

Continue ›››

BioAge Preps Brain-Penetrant NLRP3 Inhibitor for Obesity IND

BioAge Labs has finished the pre-clinical package for BGE-102, an orally available, brain-penetrant NLRP3 inhibitor that the company is advancing for obesity, and plans to submit an Investigational New Drug …

Continue ›››

Insilico Medicine's AI Designs ENPP1 Inhibitor for Immune Modulation in Cancer

A study published in Nature Communications reports the development of ISM5939, an orally active small-molecule ENPP1 inhibitor designed using Insilico Medicine’s generative AI platform. The compound works by inhibiting ENPP1, …

Continue ›››

Medable Launches Digital Long-Term Follow-Up Model for Cell and Gene Therapy Trials

Medable, a U.S.-based provider of software infrastructure for decentralized clinical trials, has introduced a digital-first Long-Term Follow-Up (LTFU) model intended for use in cell and gene therapy (CGT) trials. The …

Continue ›››

Finnish CurifyLabs Raises €6.7M to Replace Manual Compounding With Robotic Drug Manufacturing

CurifyLabs, a Finnish healthtech company, has raised €6.7 million to expand its automated solution for manufacturing compounded medications. The round was led by Springvest, a Finnish investment platform, and includes a …

Continue ›››

Biostate AI Raises $12M to Build RNA-Based Foundation Model for Molecular Diagnostics

Biostate AI has raised $12 million in Series A funding to scale its RNA sequencing platform and train a general-purpose AI model capable of predicting disease and therapy response. The …

Continue ›››

Harvard and Roche Develop Foundation AI Model to Predict and Explain Immunotherapy Response Across 33 Cancer Types

Researchers from Harvard Medical School and Roche have developed COMPASS, a foundation AI model designed to predict patient response to immune checkpoint inhibitors (ICIs) across 33 cancer types and six …

Continue ›››

Haya Therapeutics Raises $65M to Develop RNA Drugs Targeting the Dark Genome

Haya Therapeutics has raised $65 million in Series A financing to support development of therapies targeting long non-coding RNAs (lncRNAs), a regulatory layer of the genome historically dismissed as "junk …

Continue ›››

Persist AI Launches Robotic Cloud Lab for Formulation Development, Raises $12M Series A

Persist AI, a startup focused on accelerating pharmaceutical formulation development through AI-guided robotics, has launched its Cloud Lab platform and secured $12 million in Series A funding. The round was …

Continue ›››